Clinical Trial Update: A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc. [Phase 1]

View source ↗

Summary

This update notes the withdrawal of a Phase 1 study evaluating GSK945237 in healthy adults, including assessments of safety, pharmacokinetics, and potential int…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections

Drugs mentioned

• GSK945237
• Linezolid (Linezolid)
• Moxifloxacin (moxifloxacin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Bacterial | Phase 1 | Status: WITHDRAWN